BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 29779324)

  • 41. High lymphocyte counts before antithymocyte globulin administration predict acute graft-versus-host disease.
    Shiratori S; Ohigashi H; Ara T; Yasumoto A; Goto H; Nakagawa M; Sugita J; Onozawa M; Kahata K; Endo T; Hashimoto D; Teshima T
    Ann Hematol; 2021 May; 100(5):1321-1328. PubMed ID: 33215225
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Low-dose anti-thymocyte globulin plus low-dose posttransplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood for patients with hematologic malignancies: a prospective, phase II study.
    Yang J; Jiang J; Cai Y; Li S; Wan L; Zhu J; Liu H; Shao S; Bai H; Wang C; Song X
    Bone Marrow Transplant; 2019 Jul; 54(7):1049-1057. PubMed ID: 30446741
    [TBL] [Abstract][Full Text] [Related]  

  • 43. HLA 1-3 antigen-mismatched related peripheral blood stem cells transplantation using low-dose antithymocyte globulin versus unrelated cord blood transplantation.
    Wada F; Watanabe M; Konuma T; Okabe M; Kobayashi S; Uchida N; Ikegame K; Tanaka M; Sugio Y; Mukae J; Onizuka M; Kawakita T; Kuriyama T; Takahashi S; Fukuda T; Nakano N; Sawa M; Kimura T; Ichinohe T; Atsuta Y; Kanda J;
    Am J Hematol; 2022 Mar; 97(3):311-321. PubMed ID: 34978726
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation.
    Ayuk F; Diyachenko G; Zabelina T; Wolschke C; Fehse B; Bacher U; Erttmann R; Kröger N; Zander AR
    Biol Blood Marrow Transplant; 2008 Aug; 14(8):913-9. PubMed ID: 18640575
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Quality of life of patients after allogeneic hematopoietic stem cell transplantation with antihuman thymocyte globulin.
    Yu ZP; Ding JH; Wu F; Liu J; Wang J; Cheng J; Zhao G
    Biol Blood Marrow Transplant; 2012 Apr; 18(4):593-9. PubMed ID: 21846461
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Anti-thymocyte globulin improves survival free from relapse and graft-versus-host disease after allogeneic peripheral blood stem cell transplantation in patients with Philadelphia-negative acute lymphoblastic leukemia: An analysis by the Acute Leukemia Working Party of the EBMT.
    Czerw T; Labopin M; Giebel S; Socié G; Volin L; Fegueux N; Masszi T; Blaise D; Chaganti S; Cornelissen JJ; Passweg J; Maertens J; Itälä-Remes M; Wu D; Mohty M; Nagler A
    Cancer; 2018 Jun; 124(12):2523-2533. PubMed ID: 29603136
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Post-Transplant Cyclophosphamide and Thymoglobulin, a Graft-Versus-Host Disease Prophylaxis in Matched Sibling Donor Peripheral Blood Stem Cell Transplantations.
    Kunacheewa C; Owattanapanish W; Jirabanditsakul C; Issaragrisil S
    Cell Transplant; 2020; 29():963689720965900. PubMed ID: 33035116
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Outcome of allogeneic hematopoietic stem cell transplantation from HLA-matched sibling donor for 41 cases of severe aplastic anemia].
    Chen X; Wei JL; Huang Y; He Y; Yang DL; Jiang EL; Ma QL; Zhou LK; Lin XT; Shen YY; Feng SZ; Han MZ
    Zhonghua Xue Ye Xue Za Zhi; 2012 Aug; 33(8):610-4. PubMed ID: 23134851
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality.
    Sabry W; Le Blanc R; Labbé AC; Sauvageau G; Couban S; Kiss T; Busque L; Cohen S; Lachance S; Roy DC; Roy J
    Biol Blood Marrow Transplant; 2009 Aug; 15(8):919-29. PubMed ID: 19589481
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Marrow Transplantation.
    Devillier R; Labopin M; Chevallier P; Ledoux MP; Socié G; Huynh A; Bourhis JH; Cahn JY; Roth-Guepin G; Mufti G; Desmier D; Michallet M; Fegueux N; Ciceri F; Baron F; Blaise D; Nagler A; Mohty M
    Bone Marrow Transplant; 2018 Apr; 53(4):431-437. PubMed ID: 29330391
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Study on graft-versus-host disease in the allogeneic peripheral blood stem cell transplantation for the treatment of leukemia].
    Zhang WP; Wang JM; Ju XP; Song XM; Tong SP; Li HM
    Zhonghua Xue Ye Xue Za Zhi; 2003 Mar; 24(3):129-33. PubMed ID: 12697123
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Comparison of umbilical cord blood transplantation and hematopoietic stem cell transplantation from HLA-matched sibling donors in the treatment of myelodysplastic syndrome-EB or acute myeloid leukemia with myelodysplasia-related changes].
    Zhu J; Tang BL; Song KD; Zhang XH; Zhu XY; Yao W; Wan X; Liu HL; Sun ZM
    Zhonghua Xue Ye Xue Za Zhi; 2019 Apr; 40(4):294-300. PubMed ID: 31104440
    [No Abstract]   [Full Text] [Related]  

  • 53. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study.
    Bonifazi F; Solano C; Wolschke C; Sessa M; Patriarca F; Zallio F; Nagler A; Selleri C; Risitano AM; Messina G; Bethge W; Herrera P; Sureda A; Carella AM; Cimminiello M; Guidi S; Finke J; Sorasio R; Ferra C; Sierra J; Russo D; Benedetti E; Milone G; Benedetti F; Heinzelmann M; Pastore D; Jurado M; Terruzzi E; Narni F; Völp A; Ayuk F; Ruutu T; Kröger N
    Lancet Haematol; 2019 Feb; 6(2):e89-e99. PubMed ID: 30709437
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation.
    Rosenbeck LL; Kiel PJ; Kalsekar I; Vargo C; Baute J; Sullivan CK; Wood L; Abdelqader S; Schwartz J; Srivastava S; Abonour R; Robertson MJ; Nelson RP; Cornetta K; Fausel CA; Farag SS
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):916-22. PubMed ID: 20932925
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Outcomes of haploidentical peripheral blood stem cell transplantation following myeloablative conditioning using two types of rabbit ATG: a propensity score-matched analysis.
    Shi Z; Gao F; Ding D; Wu H; Shi J; Luo Y; Yu J; Tan Y; Lai X; Liu L; Fu H; Huang H; Zhao Y
    Ann Hematol; 2024 Apr; 103(4):1353-1362. PubMed ID: 38430226
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Clinical research of HLA-haploidentical peripheral hematopoietic stem cell transplantation following reduced intensity conditioning regimen with hematological malignancy patients over 50 years old].
    Liu Y; Yuan HL; Duan XL; Xu JL; Qu JH; Chen G; Shi J; Han CX; Ding LL; Jiang M
    Zhonghua Xue Ye Xue Za Zhi; 2019 Aug; 40(8):667-672. PubMed ID: 31495134
    [No Abstract]   [Full Text] [Related]  

  • 57. A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor.
    Devillier R; Fürst S; Crocchiolo R; El-Cheikh J; Castagna L; Harbi S; Granata A; D'Incan E; Coso D; Chabannon C; Picard C; Etienne A; Calmels B; Schiano JM; Lemarie C; Stoppa AM; Bouabdallah R; Vey N; Blaise D
    Am J Hematol; 2014 Jan; 89(1):83-7. PubMed ID: 24108528
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Role of Low-dose Anti-thymocyte Globulin as Standard Prophylaxis in Mismatched and Matched Unrelated Hematopoietic Peripheral Stem Cell Transplantation for Hematologic Malignancies.
    Sakellari I; Batsis I; Bousiou Z; Mallouri D; Constantinou V; Gavriilaki E; Smias C; Yannaki E; Kaloyannidis P; Papaioannou G; Stavroyianni N; Syrigou A; Sotiropoulos D; Fylaktou A; Tsompanakou A; Saloum R; Anagnostopoulos A
    Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):658-666. PubMed ID: 28716402
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [HLA-10/10 matched unrelated donor versus sibling donor hematopoietic stem cell transplantation for adult acute myeloid leukemia].
    Yao JF; Zhang GX; Shen YY; Zhang RL; He Y; Wei JL; Jiang EL; Yang DL; Feng SZ; Han MZ
    Zhonghua Xue Ye Xue Za Zhi; 2019 Jun; 40(6):460-466. PubMed ID: 31340617
    [No Abstract]   [Full Text] [Related]  

  • 60. Low-dose anti-thymocyte globulin for GVHD prophylaxis in HLA-matched allogeneic peripheral blood stem cell transplantation.
    Shiratori S; Sugita J; Ota S; Kasahara S; Ishikawa J; Tachibana T; Hayashi Y; Yoshimoto G; Eto T; Iwasaki H; Harada M; Matsuo K; Teshima T;
    Bone Marrow Transplant; 2021 Jan; 56(1):129-136. PubMed ID: 32624582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.